Teva Canada Limited, Medincell's Affiliate, Gains Canadian Approval for Risperidone LAI for Schizophrenia Treatment

Reuters
2025.09.23 17:26
portai
I'm PortAI, I can summarize articles.

Teva Canada Limited, an affiliate of Medincell’s partner Teva Pharmaceutical Industries Ltd., has received regulatory approval from Health Canada for risperidone LAI, a treatment for schizophrenia in adults. This approval marks a significant development in the pharmaceutical sector, enhancing treatment options for patients with schizophrenia.

Teva Canada Limited, an affiliate of Medincell’s partner Teva Pharmaceutical Industries Ltd., has received regulatory approval for risperidone LAI from Health Canada for the treatment of schizophrenia in adults. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medincell SA published the original content used to generate this news brief on September 23, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.